Comparing Galapagos (NASDAQ:GLPG) & Replimune Group (NASDAQ:REPL)

Galapagos (NASDAQ:GLPG) and Replimune Group (NASDAQ:REPL) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, earnings, dividends, institutional ownership, profitability, analyst recommendations and risk.

Valuation & Earnings

This table compares Galapagos and Replimune Group”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Galapagos	$298.31 million	N/A	$80.16 million	($1.57)	-20.83
Replimune Group	N/A	N/A	-$247.30 million	($3.46)	-2.81

Galapagos has higher revenue and earnings than Replimune Group. Galapagos is trading at a lower price-to-earnings ratio than Replimune Group, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Galapagos has a beta of 0.18, suggesting that its stock price is 82% less volatile than the S&P 500. Comparatively, Replimune Group has a beta of 0.66, suggesting that its stock price is 34% less volatile than the S&P 500.

Profitability

This table compares Galapagos and Replimune Group’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Galapagos	N/A	N/A	N/A
Replimune Group	N/A	-82.83%	-61.62%

Insider & Institutional Ownership

32.5% of Galapagos shares are owned by institutional investors. Comparatively, 92.5% of Replimune Group shares are owned by institutional investors. 2.9% of Galapagos shares are owned by company insiders. Comparatively, 5.2% of Replimune Group shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Galapagos and Replimune Group, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Galapagos	5	2	1	1	1.78
Replimune Group	2	2	6	1	2.55

Galapagos presently has a consensus price target of $31.33, indicating a potential downside of 4.18%. Replimune Group has a consensus price target of $9.75, indicating a potential upside of 0.31%. Given Replimune Group’s stronger consensus rating and higher possible upside, analysts plainly believe Replimune Group is more favorable than Galapagos.

Summary

Replimune Group beats Galapagos on 7 of the 12 factors compared between the two stocks.

About Galapagos

Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc.; and AbbVie S.à r.l. Galapagos NV was incorporated in 1999 and is headquartered in Mechelen, Belgium.

About Replimune Group

Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma. The company is also developing RP2, which is in Phase I clinical trials to express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trial to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.